IBB vs VGIT

iShares Biotechnology ETF vs Vanguard Intermediate-Term Treasury ETF

Quick take
  • VGIT has the lower expense ratio at 0.03% vs 0.44% for IBB.
  • VGIT pays a higher dividend yield (3.83%).

Side-by-side metrics

MetricIBBVGIT
Expense ratio
Annual fee. Lower is better.
0.44%0.03%
Dividend yield
Trailing 12-month yield.
0.23%3.83%
AUM
Assets under management — bigger funds are typically more liquid.
$7.95B$48.59B
YTD return
3.10%0.13%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
0.740.80
P/E ratio
23.72
Last price
$170.10$59.15
Inception
Issuer
iSharesVanguard

IBB top holdings

Top holdings · IBB
AMGNAmgen Inc7.37%
GILDGilead Sciences Inc7.32%
VRTXVertex Pharmaceuticals Inc7.21%
REGNRegeneron Pharmaceuticals Inc6.55%
ALNYAlnylam Pharmaceuticals Inc3.71%
ARGXargenx SE ADR3.33%
INSMInsmed Inc2.70%
BIIBBiogen Inc2.67%
NTRANatera Inc2.40%
RVMDRevolution Medicines Inc Ordinary Shares2.27%
Sector breakdown · IBB
Healthcare100.0%

VGIT top holdings

Holdings data unavailable for VGIT.

About IBB

IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $7.9B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.23%. Its largest holding is Amgen Inc (AMGN), which represents 7.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.

About VGIT

VGIT (Vanguard Intermediate-Term Treasury ETF) is Intermediate-term US Treasuries (3–10 years). Managed by Vanguard, the fund carries $48.6B in assets under management, an expense ratio of 0.03%, a dividend yield of 3.83%.